Research Papers:

Nomograms for predicting progression and efficacy of post-operation radiotherapy in IIIA-pN2 non-small cell lung cancer patients

Baozhong Zhang _, Zhiyong Yuan, Lujun Zhao, Qingsong Pang and Ping Wang

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:37208-37216. https://doi.org/10.18632/oncotarget.16564

Metrics: PDF 1503 views  |   HTML 2158 views  |   ?  


Baozhong Zhang1, Zhiyong Yuan1, Lujun Zhao1, Qingsong Pang1, Ping Wang1

1Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of China

Correspondence to:

Baozhong Zhang, email: [email protected]

Keywords: non-small cell lung cancer (NSCLC), N2, post-operative chemo-radiotherapy (POCRT), nomogram

Received: December 28, 2016     Accepted: March 16, 2017     Published: March 25, 2017


In this retrospective study, we developed nomograms for predicting the efficacy of post-operation radiotherapy (PORT) in IIIA-N2 non-small cell lung cancer (NSCLC) patients. In total, 334 patients received post-operational chemotherapy and were included in the analysis. Of those, 115 also received either concurrent or sequential post-operational radiotherapy (PORT). Nomograms were developed using Cox proportional hazard regression models to identify clinicopathological characteristics that predicted progression free survival (PFS) and overall survival (OS), and subgroup analyses of the effects of PORT were performed using nomogram risk scores. PFS and OS predicted using the nomogram agreed well with actual PFS and OS, and patients with high PFS/OS nomogram scores had poorer prognoses. In subgroup analyses, PORT increased survival more in patients with low PFS nomogram risk scores or high OS nomogram risk scores. Thus, our novel nomogram risk score model predicted PFS, OS, and the efficacy of PORT in IIIA-N2 NSCLC patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16564